Table 3.
Demographic and clinical characteristics of the subjects with different VRF burdens who provided cerebrospinal fluid (CSF) samples.
| Characteristic | Low-risk group (n = 26) | Medium-risk group (n = 22) | High-risk group (n = 11) | F or χ2 | P-value |
|---|---|---|---|---|---|
| Sex | |||||
| Malea [N, (%)] | 8 (13.56) | 15 (25.42) | 11 (18.64) | 16.77 | <0.01 |
| Femalea [N, (%)] | 18 (30.51) | 7 (11.86) | 0 (0.00) | 16.77 | <0.01 |
| Agea ( ± s, years) | 58.73 ± 6.01 | 66.55 ± 6.05 | 71.64 ± 4.93 | 22.04 | <0.01 |
| Education ( ± s, years) | 8.54 ± 2.44 | 7.55 ± 2.22 | 10.00 ± 2.90 | 3.72 | <0.05 |
| Hypertensiona [N, (%)] | 4 (6.78) | 14 (23.73) | 7 (11.86) | 13.87 | <0.01 |
| DMa [N, (%)] | 0 (0.00) | 2 (3.39) | 1 (1.69) | 2.49 | 0.29 |
| CVDa [N, (%)] | 1 (1.69) | 1 (1.69) | 4 (6.78) | 10.16 | <0.01 |
| AFa [N, (%)] | 0 (0.00) | 0 (0.00) | 3 (5.08) | 13.79 | <0.01 |
| Current Smokinga [N, (%)] | 0 (0.00) | 6 (10.17) | 4 (6.78) | 9.92 | <0.01 |
| LVHa [N, (%)] | 1 (1.69) | 0 (0.00) | 0 (0.00) | 1.29 | 0.52 |
| SBPa (mmHg) | 128.31 ± 8.75 | 137.55 ± 11.43 | 134.73 ± 10.95 | 5.07 | <0.01 |
| BUN ( ± s, mmol/L) | 4.81 ± 1.42 | 5.49 ± 1.16 | 6.27 ± 1.20 | 5.25 | <0.01 |
| UA ( ± s, μmol/L) | 303.46 ± 68.15 | 335.45 ± 101.28 | 395.82 ± 69.88 | 4.88 | <0.05 |
| TC ( ± s, mmol/L) | 4.34 ± 0.86 | 4.47 ± 1.04 | 3.83 ± 0.82 | 1.76 | 0.18 |
| TG ( ± s, mmol/L) | 1.24 ± 0.63 | 1.49 ± 0.75 | 1.16 ± 0.51 | 1.18 | 0.32 |
| HDL ( ± s, mmol/L) | 1.50 ± 0.43 | 1.34 ± 0.46 | 1.13 ± 0.49 | 2.76 | 0.07 |
| LDL ( ± s, mmol/L) | 2.36 ± 0.66 | 2.42 ± 0.77 | 2.12 ± 0.55 | 0.70 | 0.50 |
| APO-A ( ± s, mmol/L) | 1.60 ± 0.38 | 1.53 ± 0.34 | 1.32 ± 0.48 | 2.04 | 0.14 |
| FSRP ( ± s, %) | 3.12 ± 1.21 | 8.86 ± 2.23 | 19.09 ± 3.91 | 189.09 | <0.01 |
Abbreviations: DM, diabetes mellitus; CVD, cardiovascular disease; AF, atrial fibrillation; LVH, left ventricular hypertrophy on ECG; SBP, systolic blood pressure; BUN, blood urea nitrogen; UA, uric acid; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; APO-A, apolipoprotein-A; FSRP, Framingham stroke risk profile. Note: “a” indicates the risk factors for the Framingham stroke risk profile. The date are presented as means ± SD or number of cases (%).